Belumosudil
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 130 publications
RPE With ROCK-Mediated Epithelial-Mesenchymal Transition as a Key Contributor of Subretinal Fibrosis in AMD.
Journal: Investigative ophthalmology & visual science
Published: May 14, 2026
Clinical trials in graft-versus-host disease: changes in study characteristics, investigated drugs, and endpoints over time.
Journal: Transplantation and cellular therapy
Published: April 29, 2026
Correction: Real-world experience of belumosudil and belumosudil/ruxolitinib combination in steroid-refractory chronic graft-versus-host disease.
Journal: Bone marrow transplantation
Published: March 30, 2026
Identification, toxicity evaluation, and HPLC-based quality control method development of process-related impurities and degradation products of belumosudil mesylate.
Journal: Journal of pharmaceutical and biomedical analysis
Published: February 12, 2026
Beyond cytoskeletal regulation: Rho-associated, coiled-coil containing protein kinase 2 in kidney inflammation and fibrosis.
Journal: Histology and histopathology
Published: February 10, 2026
The Effect of Belumosudil on the Therapeutic Drug Levels of Tacrolimus and Sirolimus in Allogeneic Hematopoietic Transplantation.
Journal: Transplantation and cellular therapy
Published: January 30, 2026
Twenty-Year Follow-Up After Pediatric PBSCT and Living-Donor Lung Transplantation From the Original Donor: Late Benefit of Belumosudil for Chronic GVHD.
Journal: Pediatric blood & cancer
Published: January 24, 2026
Transportability to the European Population of Efficacy of Belumosudil as Compared With Physician's Choice of Best Available Therapy for the Treatment of Chronic Graft Versus Host Disease.
Journal: Transplantation and cellular therapy
Published: December 19, 2025
Optimal Treatment of Steroid-refractory Chronic Graft-versus-host Disease (cGvHD) in the Era of Novel drugs - a Systematic Review and Meta-analysis.
Journal: Stem cell reviews and reports
Published: December 05, 2025
The safety and efficacy of belumosudil and ruxolitinib combination in ruxolitinib refractory cGVHD.
Journal: Bone marrow transplantation
Published: November 27, 2025
Last Updated: 06/30/2026